Evidence map›Paper›PMID 27553024›Full record

Trial reportTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016

Downregulation of paraoxonase 3 contributes to aggressive human hepatocellular carcinoma progression and associates with poor prognosis.

Yuepeng Jin, Qiang Li, Junjun Qiu, Xiufen Zhao, Chunxiao Zheng, Shixu Lv, Yongyu Bai, Yunfeng Shan, Le-Chi Ye

Abstract readComparative StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. The Paraoxonase (International journal of molecular sciences · 2025
    Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Yuepeng JinDepartment of General Surgery, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang Province, China.
Qiang LiWenzhou Medical University, Wenzhou, Zhejiang Province, China.
Junjun QiuDepartment of Gynecology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, 200011, China.
Xiufen ZhaoDepartment of General Surgery, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang Province, China.
Chunxiao ZhengDepartment of General Surgery, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang Province, China.
Shixu LvDepartment of Gynecology, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, 200011, China.
Yongyu BaiWenzhou Medical University, Wenzhou, Zhejiang Province, China.
Yunfeng ShanDepartment of General Surgery, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang Province, China.
Le-Chi YeDepartment of Oncological Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China. yljwenzhou@126.com.
Wenzhou Medical University · CNFirst Affiliated Hospital of Wenzhou Medical University · CNObstetrics and Gynecology Hospital of Fudan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Paraoxonase (PON) enzymes possess antioxidant properties and protect against cardiovascular diseases. As a member of PON family, PON3 is primarily synthesized in the liver and poorly investigated. This study aimed to examine the expression of PON3 in human hepatocellular carcinoma (HCC) and investigate the clinical significance and biological function of PON3 in HCC patients. We first analyzed PON3 expression in 50 paired HCC samples (HCC tissues vs matched para-cancerous tissues) and 160 clinical HCC specimens by using immunohistochemistry (IHC). Our results showed that the expression of PON3 was downregulated in HCC and significantly associated with tumor-node-metastasis (TNM) stage, tumor size, and tumor number. Kaplan-Meier survival and Cox regression analyses showed that PON3 was an independent prognostic factor for overall survival (OS) and time to recurrence (TTR). Finally, we aimed to reveal the biological function of PON3 in HCC growth and metastasis, and our results showed that overexpression of PON3 potently inhibited growth and metastasis of HCC. Collectively, our study demonstrated that PON3 exhibited tumor-suppressive effects toward HCC and it might serve as a novel prognostic marker in HCC.

Indexed as

AnimalsApoptosisAryldialkylphosphataseBiomarkers, TumorBlotting, WesternCarcinoma, HepatocellularCase-Control StudiesCell MovementCell ProliferationDisease ProgressionFemaleFollow-Up StudiesHumansImmunoenzyme TechniquesLiver NeoplasmsLymphatic MetastasisAryldialkylphosphataseBiomarkers, TumorPON3 protein, humanGrowthHepatocellular carcinomaMetastasisParaoxonase 3Prognosis

Identifiers

PMID27553024
OpenAlexW2507344533

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.